Jonathan Wade Goldman MD

Oncology•Santa Monica, CA

Physician

Join to View Full Profile

2020 Santa Monica BlvdSte 600Santa Monica, CA 90404
Phone+1 310-633-8400
Fax+1 310-633-8419

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California (San Francisco)Residency, Internal Medicine, 2001 - 2004
Stanford University School of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2003 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
COMPLETED
PHASE1, PHASE2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
Completed
Phase 1, Phase 2
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29
Terminated
Phase 2
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer Start of enrollment: 2021 Jan 29
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Study of RYZ101 in Combination with SoC in Subjects with SSTR+ ES-SCLC Start of enrollment: 2022 Oct 10
RECRUITING
PHASE1
Roles: Contact
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) Start of enrollment: 2023 Sep 13
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mut...
David Planchard, Pasi A Jänne, Ying Cheng, James Chih-Hsin Yang, Noriko Yanagitani
Future Oncology. 2025-04-01
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
Roy S Herbst, Thomas John, Christian Grohé, Jonathan W Goldman, Terufumi Kato
Nature Medicine. 2025-03-17
1 citations
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01

Lectures

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

High-Dose Radiotherapy with Chemotherapy Effective in Treating People with Non-Small Cell Lung CancerJanuary 11th, 2024
Many Patients with NSCLC Receive Immunotherapy ‘Indefinitely’ – Are They Benefiting?September 18th, 2023
CASPIAN Trial Update: Phase 3 Results & PerspectivesJune 23rd, 2020
Join now to see all

Jonathan Wade Goldman MD

Dr. Goldman is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.